Mariano Viapiano博士

EDUCATION

研究抽象

纽约州立大学澳门银河平台脑肿瘤实验室和生物库

Our laboratory studies primary malignant brain cancers known as gliomas, which are highly aggressive tumors that respond poorly to conventional therapies. We analyze and target the interactions of glioma cells with other components of the tumor microenvironment, in particular neural and immune cells that can contribute to tumor growth.

我们实验室的主要研究重点是细胞外基质(ECM) that forms the scaffold of neural tissue and the changes caused in this matrix by glioma cells. 我们研究ECM重塑如何促进肿瘤侵袭, 改变神经细胞的行为, and even prevents the normal responses of immune cells against the tumor. 我们实验室目前主要进行两项调查:

-肿瘤ECM对胶质瘤免疫反应的调控: We are investigating how gliomas change the composition of ECM molecules and how different ECM components regulate the behavior of immune cells in the tumor. In this project we are also developing novel anti-ECM reagents (including novel antibodies and engineered immune cells) to target the tumor matrix and prevent tumor invasion and growth.

-针对胶质瘤-脑通讯: In this project we investigate how glioma cells respond to neural signals and release molecules that co-opt neurons and glial cells to support tumor growth. Major research in this project is focused on: 1) targeting scaffolding/polarity proteins that are needed by glioma cells to respond to pro-tumor signals from the brain; and 2) studying ECM and neuro-endocrine factors produced by "hijacked" neural cells that support the tumor cells.

Research in our Lab involves a variety of disciplines and laboratory skills, 包括分子生物学和遗传学, bioinformatics, 蛋白质生物化学, 肿瘤干细胞培养, tumor organoids, 以及恶性神经胶质瘤的动物模型. In addition, 我们是纽约州立大学上州医科大学脑瘤库的所在地, 收集了大量的肿瘤标本, tumor cells, and patient blood, 可用于基础和转化研究项目.The ultimate goal of our research is to advance novel therapeutic strategies that will improve the survival of patients with malignant brain tumors.

Figure 1: 颅内神经胶质瘤 treated with a control antibody or a novel monoclonal antibody ("mAb428.2”)对抗富含胶质瘤的ECM蛋白纤维蛋白-3. 用mAb428治疗.2 increases the infiltration of inflammatory macrophages (IBA-1+ cells) into the tumor core and reduces tumor progression (from Nandhu et al., Clin. Cancer Res., 2018)

Figure 2: A) 胶质瘤干细胞的球状体 carrying shRNA against the scaffolding protein DLG5 are grow smaller than those of control tumor cells because they cannot respond to Shh signals. B) When control and DLG5-knockdown glioma cells are introduced into new tumor spheroids the glioma cells deficient in DLG5 have less competitive fitness and eventually die out (from Kundu et al.，神经肿瘤学，2022)

Recent Articles:

• Yokoda RT, Cobb WS, Yong RL, Crary JF, Viapiano MS, Walker JM, et al. CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma. [J]神经病理学杂志. (2023) PMID: 37550258
• Pramio DT, Vieceli FM, Varella-Branco E, Goes CP, Kobayashi GS, Pelegrina DV, et al. DNA methylation of the promoter region at the CREB1 binding site is a mechanism for the epigenetic regulation of brain specific PKMzeta. 生物化学与生物物理学报-基因调控机制(2023) PMID: 36682583
• Moncao CC, Scrideli CA, Andrade AF, Viapiano MS, Carlotti CG等. Indisulam reduces viability and regulates apoptotic gene expression in pediatric high-grade glioma cells. 共同参与(2022) PMID: 36672576
• Roshini A, Goparaju C, Kundu S, Nandhu MS, Longo SL, Longo JA, Chou J, et al. The extracellular matrix protein fibulin-3/EFEMP1 promotes pleural mesothelioma growth by activation of PI3K/Akt signaling. Front. Oncol. (2022) PMID: 36303838
• Richardson TE, Walker JM, Abdullah KG, McBrayer SK, Viapiano MS, Mussa ZS, et al. 成人型弥漫性胶质瘤的染色体不稳定性. Acta Neuropathol. Commun. (2022) PMID: 35978439
• Teixeira SA, Burim RV, Viapiano MS, Bidinotto LT, Nagashi Marie SK, Fleury Malheiros SM, Oba-Shinjo SM, 安德拉德后卫和卡洛蒂后卫. 弥漫性星形细胞瘤患者的α 2 β 1整合素多态性. Front. Oncol. (2022) PMID: 35936750
• Liu Y, Sathe AA, Abdullah KG, McBrayer SK, Adams SH, Brenner AJ, et al. Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas. Acta Neuropathol. Commun. (2022) PMID: 35264242
• Kundu S, Nandhu MS, Longo SL, Longo JA, Rai S, Chin LS等. The scaffolding protein DLG5 promotes glioblastoma growth by controlling Sonic Hedgehog signaling in tumor stem cells. Neuro-Oncology (2022) PMID: 34984467
• Lustig SD, Kodali SK, Longo SL, Kundu S, Viapiano MS. Ko143通过使p -糖蛋白失活逆转胶质母细胞瘤的耐多药, 使一种对TMZ治疗具有抗性的表型变得敏感. Anticancer Res. (2022) PMID: 35093870
• Lyon JF, Vasudevaraja F, Mirchia K, Walker JM, Corona RJ, Chin LS, et al. Spatial progression and molecular heterogeneity of IDH-Mutant glioblastoma determined by DNA methylation-based mapping. Acta Neuropathol. Commun. (2021) PMID: 34193272
• Teixeira SA, Viapiano MS, Andrade AF, Nandhu MS, Pezuk JA, Bidinotto LT, et al. The carbonic anhydrase inhibitor E7070 sensitizes glioblastoma cells to radio and chemotherapy and reduces tumor growth. Mol. Neurobiol. (2021) PMID: 34085182
• Richardson TE, Sathe AA, Xing C, Mirchia K, Viapiano MS, Snuderl M, et al. Molecular signatures of chromosomal instability correlate with copy number variation patterns and patient outcome in IDH-mutant and IDH-wildtype astrocytomas. J. Neuropathol. Exp. Neurol. (2021) PMID: 33755138
• von Spreckelsen N, Fadzen CM, Hartrampf N, Ghotmi Y, Wolfe JM, Dubey S, et al. Targeting glioblastoma using a novel peptide specific to a deglycosylated isoform of brevican. Adv. Ther. (Weinh) (2021) PMID: 33997269
• Galbraith K, Kumar A, Abdullah KG, Walker JM, Adams SH, Prior T, et al. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts. J. Neuropathol. Exp. Neurol. (2020) PMID: 32647886